Nanoparticles for the treatment of the alzheimer’s disease
review article
DOI:
https://doi.org/10.29352/mill0210e.26245Keywords:
alzheimer's disease, nanomaterials, plga, nanotechnology, toxicityAbstract
Introduction: Alzheimer's Disease is a primary neurodegenerative pathology of unknown etiology and influenced by several factors with characteristic neuropathological and neurochemical features. Currently, drugs approved for the treatment of this disease only allow to relieve symptoms and are accompanied by several side effects. Nanotechnology appears as an alternative for the treatment of Alzheimer's, as it offers many advantages to modern medicine allowing a non-invasive and targeted diagnosis and treatment, reducing adverse reactions and systemic effects.
Objective: The article aims to recognize the potential of using nanoparticles in the treatment of Alzheimer's Disease, identifying the most promising treatments and their possible side effects.
Methods: A narrative bibliographic review based on consulting databases such as Science Direct, Web of Science, PubMed and Scielo.
Results: Gold nanoparticles are capable of crossing BHE, carrying essential drugs to inhibit the aggregation of Aβ peptides, as well as dissolve pre-existing fibrilla. Biodegradable and biocompatible polymers, such as polyglycolic polylactide (PLGA), are a promising and safe approach and have been widely used. The best techniques are those that guarantee that nanoparticles are capable of crossing the BHE, reach their therapeutic target, as well as guarantee that these particles do not induce toxic effects in the body. Although nanoparticles are able to treat some diseases efficiently, little is known about their side effects, they may or may not be more harmful to the body than the disease they intended to treat.
Conclusion: There are several promising therapeutic approaches, but none has yet been approved, since it is difficult to maintain adequate drug concentrations in the intraneuronal space. Establishing the toxic dose is necessary for the approved use of a nanoparticle in a treatment, but it is almost impossible to predict its cytotoxic effects in extraneuronal regions.
Downloads
References
Arabi, M. H., , H., Mirzapour, A., Ardestani, M. S. ee, & Saffari, M. (2017). Preparation of nanoliposomes containing Rosmarinus offi cinalis L essential oil; A comparative study. Bioscience Biotechnology Research Communications, 10(1), 103–108. https://doi.org/10.21786/bbrc/10.1/15
Arya, M. A., Manoj Kumar, M. K., Sabitha, M., Menon, K. N., & Nair, S. C. (2019). Nanotechnology approaches for enhanced CNS delivery in treating Alzheimer’s disease. Journal of Drug Delivery Science and Technology, 51, 297–309. https://doi.org/10.1016/j.jddst.2019.03.022
Ashraf, J. M., Ansari, M. A., Fatma, S., Abdullah, S. M. S., Iqbal, J., Madkhali, A., Hamali, A. H., Ahmad, S., Jerah, A., Echeverria, V., Barreto, G. E., & Ashraf, G. M. (2018). Inhibiting Effect of Zinc Oxide Nanoparticles on Advanced Glycation Products and Oxidative Modifications: A Potential Tool to Counteract Oxidative Stress in Neurodegenerative Diseases. Molecular Neurobiology, 55(9), 7438–7452. https://doi.org/10.1007/s12035-018-0935-x
Balducci, C., Mancini, S., Minniti, S., La Vitola, P., Zotti, M., Sancini, G., Mauri, M., Cagnotto, A., Colombo, L., Fiordaliso, F., Grigoli, E., Salmona, M., Snellman, A., Haaparanta-Solin, M., Forloni, G., Masserini, M., & Re, F. (2014). Multifunctional Liposomes Reduce Brain -Amyloid Burden and Ameliorate Memory Impairment in Alzheimer’s Disease Mouse Models. Journal of Neuroscience, 34(42), 14022–14031. https://doi.org/10.1523/JNEUROSCI.0284-14.2014
Baranowska-Wójcik, E., & Szwajgier, D. (2020). Alzheimer’s disease: Review of current nanotechnological therapeutic strategies. Expert Review of Neurotherapeutics, 20(3), 271–279. https://doi.org/10.1080/14737175.2020.1719069
Barbosa, F. O., Assis, G. B., Araújo, L. V., Pinheiro, M. J. da C., Lemos, G. D., Maia, C. S., Assis, T. de O., & Lemos-Jordão, A. J. J. M. (2020). Doença de Alzheimer e o uso de memantina: Uma revisão da literatura. Brazilian Journal of Health Review, 3(2), 2415–2425. https://doi.org/10.34119/bjhrv3n2-091
Barret, O., Alagille, D., Sanabria, S., Comley, R. A., Weimer, R. M., Borroni, E., Mintun, M., Seneca, N., Papin, C., Morley, T., Marek, K., Seibyl, J. P., Tamagnan, G. D., & Jennings, D. (2017). Kinetic Modeling of the Tau PET Tracer 18 F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects. Journal of Nuclear Medicine, 58(7), 1124–1131. https://doi.org/10.2967/jnumed.116.182881
Catalán, J., & Norppa, H. (2017). Safety Aspects of Bio-Based Nanomaterials. Bioengineering, 4(4), 94. https://doi.org/10.3390/bioengineering4040094
Dunn, B., Stein, P., & Cavazzoni, P. (2021). Approval of Aducanumab for Alzheimer Disease—The FDA’s Perspective. JAMA Internal Medicine, 181(10), 1276. https://doi.org/10.1001/jamainternmed.2021.4607
Fulop, T., Witkowski, J. M., Bourgade, K., Khalil, A., Zerif, E., Larbi, A., Hirokawa, K., Pawelec, G., Bocti, C., Lacombe, G., Dupuis, G., & Frost, E. H. (2018). Can an Infection Hypothesis Explain the Beta Amyloid Hypothesis of Alzheimer’s Disease? Frontiers in Aging Neuroscience, 10, 224. https://doi.org/10.3389/fnagi.2018.00224
Gao, C., Chu, X., Gong, W., Zheng, J., Xie, X., Wang, Y., Yang, M., Li, Z., Gao, C., & Yang, Y. (2020). Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer’s disease. Journal of Nanobiotechnology, 18(1), 71. https://doi.org/10.1186/s12951-020-00626-1
Gao, N., Sun, H., Dong, K., Ren, J., & Qu, X. (2015). Gold-Nanoparticle-Based Multifunctional Amyloid-β Inhibitor against Alzheimer’s Disease. Chemistry - A European Journal, 21(2), 829–835. https://doi.org/10.1002/chem.201404562
Geng, J., Li, M., Ren, J., Wang, E., & Qu, X. (2011). Polyoxometalates as Inhibitors of the Aggregation of Amyloid β Peptides Associated with Alzheimer’s Disease. Angewandte Chemie International Edition, 50(18), 4184–4188. https://doi.org/10.1002/anie.201007067
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., & Khachaturian, Z. S. (2018a). The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain, 141(7), 1917–1933. https://doi.org/10.1093/brain/awy132
Hampel, H., Mesulam, M.-M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2018b). Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research. The Journal Of Prevention of Alzheimer’s Disease, 1–14. https://doi.org/10.14283/jpad.2018.43
Herrán, E., Pérez-González, R., Igartua, M., Pedraz, J. L., Carro, E., & Hernández, R. M. (2013). VEGF-releasing biodegradable nanospheres administered by craniotomy: A novel therapeutic approach in the APP/Ps1 mouse model of Alzheimer’s disease. Journal of Controlled Release, 170(1), 111–119. https://doi.org/10.1016/j.jconrel.2013.04.028
Hock, F. J., & Gralinski, M. R. (Eds.). (2020). Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer International Publishing. https://doi.org/10.1007/978-3-319-68864-0
Huang, G., Xie, J., Shuai, S., Wei, S., Chen, Y., Guan, Z., Zheng, Q., Yue, P., & Wang, C. (2021). Nose-to-brain delivery of drug nanocrystals by using Ca2+ responsive deacetylated gellan gum based in situ-nanogel. International Journal of Pharmaceutics, 594, 120182. https://doi.org/10.1016/j.ijpharm.2020.120182
Jia, Y.-P., Ma, B.-Y., Wei, X.-W., & Qian, Z.-Y. (2017). The in vitro and in vivo toxicity of gold nanoparticles. Chinese Chemical Letters, 28(4), 691–702. https://doi.org/10.1016/j.cclet.2017.01.021
Karthivashan, G., Ganesan, P., Park, S.-Y., Kim, J.-S., & Choi, D.-K. (2018). Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease. Drug Delivery, 25(1), 307–320. https://doi.org/10.1080/10717544.2018.1428243
Kumar, R., Umar, A., Kumar, G., & Nalwa, H. S. (2017). Antimicrobial properties of ZnO nanomaterials: A review. Ceramics International, 43(5), 3940–3961. https://doi.org/10.1016/j.ceramint.2016.12.062
Lemoine, L., Gillberg, P.-G., Svedberg, M., Stepanov, V., Jia, Z., Huang, J., Nag, S., Tian, H., Ghetti, B., Okamura, N., Higuchi, M., Halldin, C., & Nordberg, A. (2017). Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Alzheimer’s Research & Therapy, 9(1), 96. https://doi.org/10.1186/s13195-017-0325-z
León-Silva, S., Fernández-Luqueño, F., & López-Valdez, F. (2018). Engineered Nanoparticles: Are They an Inestimable Achievement or a Health and Environmental Concern? Em F. López-Valdez & F. Fernández-Luqueño (Eds.), Agricultural Nanobiotechnology (pp. 183–212). Springer International Publishing. https://doi.org/10.1007/978-3-319-96719-6_10
Li, A., Tyson, J., Patel, S., Patel, M., Katakam, S., Mao, X., & He, W. (2021). Emerging Nanotechnology for Treatment of Alzheimer’s and Parkinson’s Disease. Frontiers in Bioengineering and Biotechnology, 9, 672594. https://doi.org/10.3389/fbioe.2021.672594
Li, Y., Cheng, Q., Jiang, Q., Huang, Y., Liu, H., Zhao, Y., Cao, W., Ma, G., Dai, F., Liang, X., Liang, Z., & Zhang, X. (2014). Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA. Journal of Controlled Release, 176, 104–114. https://doi.org/10.1016/j.jconrel.2013.12.007
Li, Z., Cong, H., Yan, Z., Liu, A., & Yu, B. (2018). The Potential Human Health and Environmental Issues of Nanomaterials. Em Handbook of Nanomaterials for Industrial Applications (pp. 1049–1054). Elsevier. https://doi.org/10.1016/B978-0-12-813351-4.00060-2
Ling, T. S., Chandrasegaran, S., Xuan, L. Z., Suan, T. L., Elaine, E., Nathan, D. V., Chai, Y. H., Gunasekaran, B., & Salvamani, S. (2021). The Potential Benefits of Nanotechnology in Treating Alzheimer’s Disease. BioMed Research International, 2021, 1–9. https://doi.org/10.1155/2021/5550938
Ma, R., Zhang, Y., Hong, X., Zhang, J., Wang, J.-Z., & Liu, G. (2017). Role of microtubule-associated protein tau phosphorylation in Alzheimer’s disease. Journal of Huazhong University of Science and Technology [Medical Sciences], 37(3), 307–312. https://doi.org/10.1007/s11596-017-1732-x
Marinho, K. S. N., Antonio, E. A., Silva, C. V. N. S., Silva, K. T. D., Teixeira, V. W., Aguiar Junior, F. C. A. D., Santos, K. R. P. D., Silva, N. H. D., & Santos, N. P. S. (2017). Hepatic toxicity caused by PLGA-microspheres containing usnic acid from the lichen C ladonia substellata (AHTI) during pregnancy in Wistar rats. Anais Da Academia Brasileira de Ciências, 89(2), 1073–1084. https://doi.org/10.1590/0001-3765201720160650
Menghani, Y. R., Bhattad, D. M., Chandak, K. K., Taksande, J. R., & Umekar, M. J. (2021). A Review: Pharmacological and herbal remedies in The Management of Neurodegenerative disorder (Alzheimer’s). International Journal of Pharmacognosy and Life Science, 2(1), 18–27. https://doi.org/10.33545/27072827.2021.v2.i1a.23
Menon, J. U., Kona, S., Wadajkar, A. S., Desai, F., Vadla, A., & Nguyen, K. T. (2012). Effects of surfactants on the properties of PLGA nanoparticles. Journal of Biomedical Materials Research Part A, 100A(8), 1998–2005. https://doi.org/10.1002/jbm.a.34040
Nikolova, M., Slavchov, R., & Nikolova, G. (2020). Nanotechnology in Medicine. Em F. J. Hock & M. R. Gralinski (Eds.), Drug Discovery and Evaluation: Methods in Clinical Pharmacology (pp. 533–546). Springer International Publishing. https://doi.org/10.1007/978-3-319-68864-0_45
Nishu, S. D., Park, S., Ji, Y., Han, I., Key, J., & Lee, T. K. (2020). The effect of engineered PLGA nanoparticles on nitrifying bacteria in the soil environment. Journal of Industrial and Engineering Chemistry, 84, 297–304. https://doi.org/10.1016/j.jiec.2020.01.011
Organization for Economic Cooperation and Development. (2017). Health at a Glance 2017: OECD Indicators. OECD. https://doi.org/10.1787/health_glance-2017-en
Ono, M., Sahara, N., Kumata, K., Ji, B., Ni, R., Koga, S., Dickson, D. W., Trojanowski, J. Q., Lee, V. M.-Y., Yoshida, M., Hozumi, I., Yoshiyama, Y., van Swieten, J. C., Nordberg, A., Suhara, T., Zhang, M.-R., & Higuchi, M. (2017). Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain, 140(3), 768-780. https://doi.org/10.1093/brain/aww339
Pramanik, D., Ghosh, C., & Dey, S. G. (2011). Heme–Cu Bound Aβ Peptides: Spectroscopic Characterization, Reactivity, and Relevance to Alzheimer’s Disease. Journal of the American Chemical Society, 133(39), 15545–15552. https://doi.org/10.1021/ja204628b
Sajid, M., & Płotka-Wasylka, J. (2020). Nanoparticles: Synthesis, characteristics, and applications in analytical and other sciences. Microchemical Journal, 154, 104623. https://doi.org/10.1016/j.microc.2020.104623
Sharma, N., Tramutola, A., Lanzillotta, C., Arena, A., Blarzino, C., Cassano, T., Butterfield, D. A., Di Domenico, F., Perluigi, M., & Barone, E. (2019). Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer’s disease. Neurobiology of Disease, 125, 176–189. https://doi.org/10.1016/j.nbd.2019.02.003
Sousa, B. M. (2017). Abordagem Terapêutica na Doença de Alzheimer (Dissertação de Mestrado, Faculdade de Ciências e Tecnologia da Universidade do Algarve). http://hdl.handle.net/10400.1/10408
Taylor, M., Moore, S., Mourtas, S., Niarakis, A., Re, F., Zona, C., Ferla, B. L., Nicotra, F., Masserini, M., Antimisiaris, S. G., Gregori, M., & Allsop, D. (2011). Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer’s Aβ peptide. Nanomedicine: Nanotechnology, Biology and Medicine, 7(5), 541–550. https://doi.org/10.1016/j.nano.2011.06.015
Vaz, M., & Silvestre, S. (2020). Alzheimer’s disease: Recent treatment strategies. European Journal of Pharmacology, 887, 173554. https://doi.org/10.1016/j.ejphar.2020.173554
Walsh, S., Merrick, R., Milne, R., & Brayne, C. (2021). Aducanumab for Alzheimer’s disease? BMJ, 374, n1682. https://doi.org/10.1136/bmj.n1682
Yang, M., Jin, L., Wu, Z., Xie, Y., Zhang, P., Wang, Q., Yan, S., Chen, B., Liang, H., Naman, C. B., Zhang, J., He, S., Yan, X., Zhao, L., & Cui, W. (2021). PLGA-PEG Nanoparticles Facilitate In Vivo Anti-Alzheimer’s Effects of Fucoxanthin, a Marine Carotenoid Derived from Edible Brown Algae. Journal of Agricultural and Food Chemistry, 69(34), 9764–9777. https://doi.org/10.1021/acs.jafc.1c00569
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020). Current and future treatments in Alzheimer disease: An update. Journal of Central Nervous System Disease, 12, 1-12. https://doi.org/10.1177/1179573520907397
Zeng, H., Qi, Y., Zhang, Z., Liu, C., Peng, W., & Zhang, Y. (2021). Nanomaterials toward the treatment of Alzheimer’s disease: Recent advances and future trends. Chinese Chemical Letters, 32(6), 1857–1868. https://doi.org/10.1016/j.cclet.2021.01.014
Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., Chen, Q., Chen, H., Ma, F., An, Y., Xiao, L., Jiang, C., Shi, L., Kang, C., & Liu, Y. (2019). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-Amyloid Aggregates in Alzheimer’s disease mice. Nano Letters, 19(2), 674–683. https://doi.org/10.1021/acs.nanolett.8b03644
Zhang, L., Zhao, P., Yue, C., Jin, Z., Liu, Q., Du, X., & He, Q. (2019). Sustained release of bioactive hydrogen by Pd hydride nanoparticles overcomes Alzheimer's disease. Biomaterials, 197, 393-404. https://doi.org/10.1016/j.biomaterials.2019.01.037
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Millenium - Journal of Education, Technologies, and Health
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who submit proposals for this journal agree to the following terms:
a) Articles are published under the Licença Creative Commons (CC BY 4.0), in full open-access, without any cost or fees of any kind to the author or the reader;
b) The authors retain copyright and grant the journal right of first publication, allowing the free sharing of work, provided it is correctly attributed the authorship and initial publication in this journal;
c) The authors are permitted to take on additional contracts separately for non-exclusive distribution of the version of the work published in this journal (eg, post it to an institutional repository or as a book), with an acknowledgment of its initial publication in this journal;
d) Authors are permitted and encouraged to publish and distribute their work online (eg, in institutional repositories or on their website) as it can lead to productive exchanges, as well as increase the impact and citation of published work
Documents required for submission
Article template (Editable format)